AlphaMol Science files first-in-human trial for CSU drug Alpha-0261
The Phase Ib registration gives no target, no primary endpoint efficacy bar and no comparator arm, leaving safety in a 48-patient cohort as the only near-term signal.
Executive Summary
- AlphaMol Science Ltd. registered a Phase Ib, randomized, double-blind, placebo-controlled trial of Alpha-0261 in chronic spontaneous urticaria, with a primary completion date of March 30, 2027 NCT07684560Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2).NCT07684560.
- The registry discloses no molecular target and no mechanism of action for Alpha-0261, so the trial cannot yet be placed on a competitive map by mechanism.
- The primary endpoint is a safety measure, frequency of treatment-emergent adverse events, not an efficacy bar; UAS7 symptom scoring is only a secondary endpoint at Week 4 Press ReleasePress ReleaseJul 6, 2026.
- The trial enters a field with 8 active CSU studies and 2,804 total enrolled patients, five of them already in Phase 3, meaning Alpha-0261 starts several years and stages behind the leaders.
- AppliedXL has no probability read on record for this catalyst, and no readout-timing forecast is available for this trial.
The filing
AlphaMol Science Ltd. (Shanghai) added NCT07684560 to ClinicalTrials.gov on July 6, 2026, registering a Phase Ib, randomized, double-blind, placebo-controlled, dose-escalation study of Alpha-0261 tablets NCT07684560+1Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2).NCT07684560Press ReleaseJul 6, 2026. The trial runs in two parts: Part 1 tests safety and tolerability in patients with chronic spontaneous urticaria (CSU), and Part 2 assesses food effect in healthy adults Press ReleasePress ReleaseJul 6, 2026. The study has not yet begun recruiting, targets 48 participants, and lists a primary completion date of March 30, 2027. The trial is based at a single site in China.
The endpoint bar
The registered primary outcome is "frequency of treatment emergent adverse events," covering incidence, severity, and relationship to study drug of adverse events, serious adverse events, and adverse events leading to discontinuation Press ReleasePress ReleaseJul 6, 2026. That is a safety endpoint, not an efficacy readout. The only disease-activity measure, change from baseline in Weekly Urticaria Activity Score (UAS7) at Week 4, is listed as secondary. A result from this trial, when it reads out, will speak to tolerability and dosing, not to whether Alpha-0261 controls CSU symptoms.
The missing mechanism
AppliedXL's mechanism-classification tool returned no result for Alpha-0261, and the registry itself lists the drug's target as unknown. Because first-in-class status requires a known target, the seed's competitive model marks Alpha-0261 as neither first-in-class nor a clear fast-follower; its mechanism basis is simply undisclosed. That absence limits how investors can size up Alpha-0261 against the field's dominant approaches: BTK inhibition (Novartis's remibrutinib, Sanofi's rilzabrutinib), anti-KIT antibodies (Celldex's barzolvolimab), IgE-targeting antibodies (Jemincare's ozureprubart), and IL-4Rα blockade (Shanghai Mabgeek's MG-K10).
A crowded field
The CSU landscape carries 8 active trials and 2,804 enrolled patients across the tracked comparator set, with 62% of that activity already in Phase 3. Leading Phase 3 candidates include Celldex's barzolvolimab, Jemincare's ozureprubart, and Beijing InnoCare's ICP-332, each years ahead of Alpha-0261 on the development timeline. AppliedXL's readthrough scoring flags the closest beneficiary of a positive Alpha-0261 signal as Hangzhou Highlightll's TLL-018, a same-modality, same-indication small molecule now in its own Phase Ib/IIa study, with a composite readthrough score of 0.57.
What the trial can establish
Because Part 1 is randomized and placebo-controlled even at Phase Ib, dosing decisions here rest on a comparator arm rather than an open-label impression, which is a more disciplined design choice than many first-in-human CSU studies use. Protocol-stability tracking shows zero registry changes since the initial filing, a stable label reflecting the trial's newness rather than any track record. With enrollment not yet started and no historical outcomes on file for this drug, the trial's information value today is limited to establishing that a randomized safety study exists and is on the registry, not to any signal about the drug's clinical prospects.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.